menu search

Gritstone bio presents 6-month neutralizing antibody (nab) data at eccmid 2023 from two phase 1 studies evaluating self-amplifying mrna (samrna) against sars-cov-2 (coral)

— CORAL-CEPI: Primary series samRNA vaccination elicits strong neutralizing antibody (nAb) responses that persist for at least 6 months, including v...

April 17, 2023, 11:01 am

Investors who lost over $200,000 with rite aid corporation (nyse: rad) shares should contact the shareholders foundation in connection with the lawsuit

SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) — The Shareholders Foundation, Inc. announces that a deadline is coming up in the lawsuit that was filed ...

April 17, 2023, 9:55 am

Aud/usd – australian dollar takes traders for a wild ride

The Australian dollar has steadied on Monday, trading just above the 0.67 level. We could see further movement from the Aussie early on Tuesday, as Ch...

April 17, 2023, 8:55 am

Aussie takes traders for a wild ride

US retail sales decelerate sharply in May US bank earnings were solid Markets have priced a May rate hike at 80% AUD/USD steady after swings of over 1...

April 17, 2023, 8:19 am

From ge to siemens, the wind energy industry hopes billions in losses are about to end

For wind turbine makers GE, Siemens and Vestas, the Inflation Reduction Act tax credits and subsidies are a lifeline for a renewable energy industry i...

April 17, 2023, 7:50 am

Eleven people die of sunstroke near mumbai after open-air award function

MUMBAI (Reuters) – At least eleven people died on Sunday after suffering from sunstroke at an event attended by India’s home minister on the outsk...

April 17, 2023, 4:48 am

Merck makes us$11bn swoop for california biotech

Merck & Co Inc (NYSE:MRK) is set to acquire Prometheus Biosciences for $10.8bn in an all-cash deal, as the US drugmaker aims to bolster its pipeline....

April 17, 2023, 3:13 am

Gsk reports positive phase 3 data for uti oral antibiotic

GSK PLC GSK, -0.49% on Monday reported positive data from its phase 3 studies for gepotidacin, its late-stage oral antibiotic for uncomplicated urinar...

April 17, 2023, 2:58 am

Gold steadies above $2,000 as markets reassess fed risks

Gold prices steadied in early Asian trade on Monday, holding on to key levels after hawkish comments from Federal Reserve officials on the path of int...

April 17, 2023, 1:14 am

Four turkish troops wounded in attacks in syria, ankara says

ISTANBUL (Reuters) – Four Turkish soldiers were wounded in artillery and rocket attacks by Kurdish militants on bases in northern Syria, prompting a...

April 16, 2023, 8:33 pm

France’s ynsect to refocus bug business after capital increase

By Sybille de La Hamaide PARIS (Reuters) – French insect-based ingredients maker Ynsect will refocus its strategy on high-margin markets like pet fo...

April 16, 2023, 8:19 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm

Vaxcyte to host webcast and conference call to discuss results from phase 2 study of its 24-valent pneumococcal conjugate vaccine candidate in adults aged 65 and older and full six-month safety data f

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fide...

April 16, 2023, 5:00 pm


Search within

Pages Search Results: